Psychopharmacology: Clinical Implications of Brain Neurochemistry

Pediatric Clinics of North America

Volumn 53, Issue 4, 2006, Pages 767-775

  Scheffer, Russell E ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CLONIDINE; FLUOXETINE; FLUVOXAMINE; GUANFACINE; IMIPRAMINE; LITHIUM SALT; METHYLPHENIDATE; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGGRESSION; AKATHISIA; ANHEDONIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; AUTONOMIC NERVOUS SYSTEM; BEHAVIOR; BEHAVIOR DISORDER; BIPOLAR DISORDER; BRAIN; CELL ORGANELLE; DEPRESSION; DEVELOPMENT; DISEASE EXACERBATION; DYSTONIA; ELECTROCARDIOGRAM; EMOTION; ENURESIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TRACT; HOMEOSTASIS; HUMAN; IMPULSIVENESS; MAJOR DEPRESSION; MANIA; MENTAL DISEASE; MIGRAINE; MOTOR DYSFUNCTION; NERVE CELL; NEUROCHEMISTRY; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PRESCRIPTION; PROLACTIN BLOOD LEVEL; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; RISK; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SYNAPSE; TREMOR; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; AUTISTIC DISORDER; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; ELECTROCARDIOGRAPHY; HUMANS; MENTAL DISORDERS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 33746228232     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2006.05.012     Document Type: Review

References (12)

1. Riddle M.A., Labellarte M.J., and Walkup J.T. Pediatric psychopharmacology: problems and prospects. J Child Adolesc Psychopharmacol 8 2 (1998) 87-97
2. Walkup J.T., Cruz K., Kane S., et al. The future of pediatric psychopharmacology. Pediatr Clin North Am 45 5 (1998) 1265-1278
3. DeBar L.L., Lynch F., Powell J., et al. Use of psychotropic agents in preschool children: associated symptoms, diagnoses, and health care services in a health maintenance organization. Arch Pediatr Adolesc Med 157 2 (2003) 150-157
4. Greenhill L.L., Vitiello B., Abikoff H., et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry 42 6 (2003) 651-655
5. Whitaker-Azmitia P.M., Druse M., Walker P., et al. Serotonin as a developmental signal. Behav Brain Res 73 1-2 (1996) 19-29
6. Breese G.R., Baumeister A.A., McCown T.J., et al. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J Pharmacol Exp Ther 231 2 (1984) 343-354
7. Cameron H.A., Hazel T.G., and McKay R.D. Regulation of neurogenesis by growth factors and neurotransmitters. J Neurobiol 36 2 (1998) 287-306
8. Olfson M., Shaffer D., Marcus S.C., et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60 10 (2003) 978-982
9. Carrey N. Developmental neurobiology: implications for pediatric psychopharmacology. Can J Psychiatry 46 9 (2001) 810-818
10. Blair J., Taggart B., and Martin A. Electrocardiographic safety profile and monitoring guidelines in pediatric psychopharmacology. J Neural Transm 111 7 (2004) 791-815
11. Tosyali M.C., and Greenhill L.L. Child and adolescent psychopharmacology. Important developmental issues. Pediatr Clin North Am 45 5 (1998) 1021-1035 [vii.]
12. Findling R.L. Paediatric psychopharmacology: closing the gap between science and practice. Expert Opin Pharmacother 2 4 (2001) 523-525